ERBB2 and breast carcinoma: Trastuzumab is a humanized MoAb specific for the extracellular domain of HER2 that has been selected for its ability to block HER2 signaling after binding to the receptor HER2 is overexpressed in approximately 30% of breast cancers and is associated with a more severe prognosis [43, 44].